AHAbdulrahman Khaldoon Hamid

Abdulrahman Khaldoon Hamid

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abdulrahman Khaldoon Hamid has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Assessment of Knowledge, Attitude, and Anxiety among Healthcare Providers and Medical Students in Iraq about Monkeypox Virus during the 2024 Global Outbreak

    by Nabeel Al-Fatlawi, Abdulrahman Khaldoon Hamid, Ghadeer Ali Hassan, Sajjad Ghanim Al-Badri, Sajjad K. Naseem, Yousif Ali Madlul, Noran Muhsin Al-Gizey, Fatimah Al-Shujairi, Osama Al-Fatlawi, Ahmed Dheyaa Al-Obaidi

    The resurgence of monkeypox (MPX) as a global public health emergency in 2024 highlighted the challenges faced by healthcare systems worldwide, particularly in resource-limited settings like Iraq. Understanding the knowledge, attitudes, and anxiety levels among healthcare providers and medical students is crucial to enhance preparedness and response strategies during outbreaks. This study aimed to evaluate the knowledge, attitudes, and anxiety levels of Iraqi healthcare providers and medical students regarding MPX, identifying gaps that may hinder effective outbreak response and public health education. A cross-sectional study was conducted among healthcare providers and medical students across Iraq. Data were collected through an online, self-administered survey distributed via digital platforms between September 1, 2024, and January 15, 2025. The questionnaire assessed participants’ knowledge, attitudes, and anxiety regarding MPX. A total of 200 participants were included, with a mean age of 21.84 ± 2.49 years, predominantly female (74%) and single (96%). While 73.8% of participants recognized isolation as a prevention method, 63.8% identified multiple transmission routes, and only 40% were aware of MPX prior to the study. The average anxiety score was 17.92 ± 5.76, reflecting moderate anxiety, with higher scores observed among females. Knowledge gaps persisted in recognizing symptoms like lymphadenopathy (51.3%) and treatment options, with 38.8% believing there was no treatment. Vaccination willingness was moderate, with only 65% willing to be vaccinated. Social media was the primary source of information (63.7%), often contributing to misinformation. Significant gaps in knowledge and varying attitudes highlight the need for targeted educational campaigns and improved communication strategies to prepare healthcare professionals for managing emerging infectious diseases like MPX. Addressing these gaps can mitigate anxiety and enhance healthcare preparedness in Iraq and similar settings.

  • Assessing the efficacy of trigeminal nerve stimulation for drug-resistant epilepsy: A systematic review and meta-analysis

    by Abdullah Yousef Aldalati, Abbas F. Abdul Hussein, Abdulrahman Khaldoon Hamid, Mohammad Al Diab Al Azzawi, Mohamed Rifai, Mohamed Fawzi Hemida, Humam L. Hammood, Aya M. Khanfas, Abdullah Hammadi Hussein, Mina Khalis Khalid, et al.

    The management of drug-resistant epilepsy (DRE) is challenging as the conventional anti-epileptic drugs have failed to control seizures in these patients. In recent years, neuromodulation therapies have gained attention, specifically trigeminal nerve stimulation(TNS) for seizure control has emerged as an effective therapeutic option. However, its precise effectiveness, particularly as measured by response rates and seizure reduction rates, remains debated. In accordance with PRISMA guidelines, we performed a meta-analysis of the existing original studies across PubMed, SCOPUS, Cochrane, and Web of Science medical databases from inception to 31 October 2024. We aimed to include studies discussing trigeminal nerve stimulation, to evaluate the efficacy and safety of TNS in managing DRE. A total of 9 eligible studies were included. Our meta-analysis included nine studies with a total of 411 patients. Pooled analysis of double-arm studies demonstrated that TNS significantly increased the response rate at 3 months (RR 2.03, 95% CI [1.07, 3.84], P-value for effect = 0.03). The effect was not significant at 6 or 12 months (6 months: RR 3.00, 95% CI [0.41, 21.98], P-value for effect = 0.28; 12 months: RR 3.24, 95% CI [0.39, 26.97], P-value for effect = 0.28). TNS showed borderline statistical significance reduction in seizure frequency compared to sham at 3 months (RR 2.85,95%CI[0.99,8.22], P = 0.05). The effect was not significant at 6 or 12 months (6 months: RR 3.01,95% CI[0.44, 20.58], P = 0.26; 12 months: RR 3.26,95%CI[0.38,27.68], P = 0.28). In single-arm analysis, the pooled proportion of patients achieving a response (≥ 50% seizure reduction) was 42% (95% CI: 30% to 54%) at 3 months, 48% (95% CI: 36% to 61%) at 6 months, and 45% (95% CI: 30% to 60%) at 12 months. The mean percentage seizure reduction was 29% (95% CI: 8% to 51%) at 3 months, 40% (95% CI: 28% to 52%) at 6 months, and 46% (95% CI: 29% to 62%) at 12 months. This meta-analysis provides evidence supporting TNS as a well-tolerated therapy with a statistically significant short-term effect at 3 months. Point estimates at 6 and 12 months suggest potential long-term benefit, but the evidence is fragile due to imprecise and wide confidence intervals. Larger randomized trials are needed to confirm the long-term efficacy of TNS for DRE.


  • Outcomes of early high-flow nasal cannula (HFNC) use in pediatric respiratory distress in acute settings: a meta-analysis

    by Mohammed Alsabri, Abdulrahman Khaldoon Hamid, Dina Essam Abo-Elnour, Wafaa Shehada, Shree Rath, Amira A. Aboali

    With the increasing incidence of pneumonia and acute respiratory distress in pediatric populations, effective oxygen delivery techniques are crucial for improving clinical outcomes. However, a debate exists across current studies on the use of high-flow nasal cannula (HFNC), and whether its benefits outweight the overutilization in a hospital setting. This systematic review and meta-analysis evaluates HFNC therapy in comparison to conventional oxygen therapy and noninvasive ventilation (NIV). A literature search was conducted to identify studies comparing HFNC to other oxygen delivery modalities in pediatric populations with acute respiratory distress were included. Outcomes include intubation rates, hospital and ICU stays, adverse events, and mortality. Statistical analysis was performed using RevMan software. A total of 10 studies comprising 7,762 patients were identified for quantitative analysis. HFNC significantly reduced intubation rates compared to conventional oxygen therapy (OR = 0.55, 95% CI: 0.34–0.89, p = 0.01). It also reduced ICU length of stay compared to NIV (MD = -2.76, 95% CI: -4.98 to -0.53, p = 0.02) and was associated with a lower mortality risk compared to NIV (OR = 0.62, 95% CI: 0.44–0.86, p = 0.005). However, HFNC did not show significant differences in success rates or adverse events when compared to either oxygen therapy or NIV. Conclusion: HFNC demonstrates substantial benefits in reducing intubation rates and ICU stays compared to conventional oxygen therapy and NIV. While HFNC appears promising for pediatric respiratory distress management, increased ICU admissions and longer hospital stays remain areas for further research. What is Known: • Acute respiratory distress syndrome (ARDS) is a leading cause of morbidity and mortality in pediatric populations globally. High-flow nasal cannula (HFNC) therapy is a non-invasive oxygen delivery method that reduces inspiratory resistance and provides higher oxygen flow. • HFNC has been associated with reduced intubation rates compared to conventional oxygen therapy in past studies. • Non-invasive ventilation (NIV) and conventional oxygen therapy are established methods for respiratory support but present with limitations such as higher intubation rates and risks of complications. What is New: • HFNC significantly reduces intubation rates compared to conventional oxygen therapy (OR = 0.55, p = 0.01) and is associated with shorter ICU stays compared to NIV (MD = -2.76 days, p = 0.02). • However, HFNC does not show significant advantages in success rates or adverse events compared to other oxygen delivery methods. HFNC also resulted in longer hospital stays compared to conventional oxygen therapy (MD = 0.38 days, p = 0.01). The study highlights the need for judicious use of HFNC and the establishment of standardized clinical guidelines to optimize its use.


  • Open Access

    Nasopharyngeal carcinoma with unusual metastatic spread to the spine and meninges: a case report with literature review

    by Salma Swadi Yassen, Sajjad Ghanim Al-Badri, Ali Naser Aldarawsha, Mohamed Samy Elazab, Asdah Alawad, Ameer Dhahir Hameedi, Abdulrahman Khaldoon Hamid, Hussein Mohsin Hasan, Nabeel Al-Fatlawi, Hasan Ali Asghar

    Nasopharyngeal carcinoma (NPC) is an epithelial malignancy commonly associated with Epstein–Barr virus infection. While bone, liver, and lung metastases are well-documented, central nervous system (CNS) involvement, particularly spinal and meningeal metastases, is extremely rare. We present a 41-year-old male with nasal obstruction and diplopia, diagnosed with locally advanced NPC. After treatment with chemotherapy and intensity-modulated radiotherapy, the patient achieved excellent locoregional control. However, months later, he developed persistent back pain, and imaging revealed metastatic deposits in the spine and meninges. Histopathological analysis confirmed metastatic NPC despite resolution of the primary tumor. The patient received palliative radiotherapy and intrathecal chemotherapy, but disease progression highlighted the aggressive nature and poor prognosis of CNS metastases in NPC. This case underscores the need for advanced imaging, histological confirmation, and tailored therapies in managing rare NPC metastases, with long-term follow-up and innovative therapies critical for improving outcomes in advanced disease.


  • What is the impact of Kinesio taping on anterior cruciate ligament reconstruction: a systematic review and meta-analysis

    by Amr Elrosasy, Mohamed Abo Zeid, Ahmed W. Abbas, Hatem Eldeeb, Ghaith Y. Eljadid, Abdulrahman Khaldoon Hamid, Mohammad Al Diab Al Azzawi

    Purpose As a therapeutic intervention for several musculoskeletal illnesses, the benefits and effectiveness of Kinesio taping (KT) are currently unclear. This systematic review and meta-analysis's (MA) goal is to evaluate the effectiveness of KT for anterior cruciate ligament (ACL) reconstruction and its impact on clinical outcomes. Methods A comprehensive search of online databases was done to discover relevant studies. Inclusion criteria included controlled or randomized clinical trials that were published in English. Changes in pain, flexion strength, and extension strength were among the outcomes of interest. RevMan 5.4 was used to extract and analyze data. Results After satisfying the inclusion requirements, five studies were included in the MA. Pooled analysis showed that, in comparison with the intervention group, the control group had a statistically significant improvement in flexion strength (Standardized mean difference (SMD) = 0.44, 95% Confidence interval (CI) [0.01, 0.87], p = 0.04). Extension strength and pain, however, did not significantly differ between the intervention and control groups (SMD = 30, 95% CI [− 0.12, 0.72], p = 0.16), (SMD = 0.26, 95% CI [− 0.14, 0.66], p = 0.20), respectively. Conclusions This analysis suggests limited to no benefits of KA post-ACL reconstruction. While the control group surprisingly showed better improvement in flexion strength, no significant differences were found in extension strength and pain. Further rigorous trials are needed to confirm its utility in rehabilitation.


  • Open Access

    Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis

    by Abdulrahman Khaldoon Hamid, AbdulJaber A’Ed Tayem, Sandra Thair Al-Aish, Ahmed Sermed Al Sakini, Dalia Dhia Hadi, Rami Thair Al-Aish

    Background: Heart failure (HF) is a highly prevalent disease, among the primary factors contributing to morbidity and death. One of its types is heart failure with preserved ejection fraction (HFpEF) comprising 40%–50% of newly diagnosed HF cases. Despite the high prevalence of HFpEF, there is still a lack of knowledge regarding the best drugs and treatment approaches to be used. However, the sodium-glucose co-transporter 2 (SGLT2) inhibitors could be a promising treatment. Objectives: To examine SGLT2 inhibitors’ effect on hospitalization, cardiovascular death, and estimated glomerular filtration rate (eGFR) in HFpEF patients. Search methods: We conducted searches for randomized controlled trials (RCTs) in PubMed, Embase, Scopus, and Web of Science up to July 2024. Selection criteria: We chose RCTs that examined the effects of SGLT2 inhibitors and placebo in individuals with higher than 40% ejection fraction (HFpEF). Data collection and analysis: The methodology for the systematic review and meta-analysis was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis. Main results: We included 8 studies with 16,509 participants. Drugs examined in our paper included empagliflozin, dapagliflozin, sotogliflozin, and ertugliflozin. Various outcomes were analyzed in different papers. However, different SGLT2 inhibitors lead to a decreased risk of cardiovascular hospitalization and kidney injury. Our meta-analysis showed a decreased risk of cardiovascular hospitalization but not death due to cardiovascular causes or other causes. These results were regardless of baseline status of eGFR, systolic blood pressure, atrial fibrillation or flutter, diabetes mellitus, sex, body mass index, and nt-proBNP. The included studies were of moderate to high quality. Conclusion: For individuals with HFpEF, SGLT2 inhibitors have been proven to be a safe and effective medication. However, more studies are needed for longer durations, reporting adverse events, effects on exercise tolerance, and other secondary outcomes.